ESPERION THERAPEUTICS INC. - COMMON STOCK

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

10 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ESPERION THERAPEUTICS INC. - COMMON STOCK

09 Apr 2025 06:49:19 By NetDania Notify

NetDania - New 12 months Low: ESPERION THERAPEUTICS INC. - COMMON STOCK

08 Apr 2025 07:58:43 By NetDania Notify

NetDania - New 12 months Low: ESPERION THERAPEUTICS INC. - COMMON STOCK

07 Apr 2025 06:49:40 By NetDania Notify

NetDania - New 12 months Low: ESPERION THERAPEUTICS INC. - COMMON STOCK

04 Apr 2025 06:45:29 By NetDania Notify

NetDania - New 12 months Low: ESPERION THERAPEUTICS INC. - COMMON STOCK

03 Apr 2025 06:45:16 By NetDania Notify

NetDania - New 12 months Low: ESPERION THERAPEUTICS INC. - COMMON STOCK

01 Apr 2025 06:47:58 By NetDania Notify

Esperion Appoints Robert E. Hoffman to Board of Directors

01 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ESPERION THERAPEUTICS INC. - COMMON STOCK

31 Mar 2025 06:45:23 By NetDania Notify

Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference

24 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

20 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ESPERION THERAPEUTICS INC. - COMMON STOCK

13 Mar 2025 08:12:11 By NetDania Notify

NetDania - New 12 months Low: ESPERION THERAPEUTICS INC. - COMMON STOCK

11 Mar 2025 07:17:10 By NetDania Notify

NetDania - New 12 months Low: ESPERION THERAPEUTICS INC. - COMMON STOCK

07 Mar 2025 06:47:06 By NetDania Notify

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

04 Mar 2025 03:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ESPERION THERAPEUTICS INC. - COMMON STOCK

03 Mar 2025 12:24:27 By NetDania Notify

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

03 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

18 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

13 Feb 2025 13:30:00 By Nasdaq GlobeNewswire

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

09 Jan 2025 05:00:00 By Nasdaq GlobeNewswire